Modus Therapeutics pauses enrollment in Phase IIa sevuparin trial after serious adverse event

Bitget2026/10/14 18:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Modus Therapeutics voluntarily paused enrollment in Part 2 of its Phase IIa sevuparin trial for chronic kidney disease with anemia.
A serious adverse event prompted the precautionary pause; a causal link to sevuparin has not been established.
The pause was not regulator-imposed; no ongoing patient treatment required discontinuation.
Proof-of-concept results are now expected in the first quarter of 2027, versus around the turn of 2026/2027 previously.
Cash is expected to fund operations into the second quarter of 2027; an updated financing assessment is due November 24, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modus Therapeutics Holding AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Modus Therapeutics pauses enrollment in Phase IIa sevuparin trial after serious adverse event

You may also like

Crypto prices